Ivermectin with immunotherapy for metastatic triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older.
- Your cancer is metastatic triple-negative breast cancer confirmed by lab tests (ER/PR very low and HER2 negative).
- Your cancer has gotten worse after 1–2 prior drug treatments for metastatic disease.
- You’re well enough to participate (ECOG 0–1) and expected to live more than 3 months.
- You must have measurable or “evaluable” tumor spots on scans, and you’ve mostly recovered from prior treatment side effects.
- Your blood and organ tests (like white blood cells, platelets, liver, kidneys, and heart function) are within allowed ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
This trial tests a new combination of radiation plus an immunotherapy drug (pembrolizumab) to help your immune system fight metastatic triple-negative breast cancer after a prior immunotherapy has stopped working. The goal is to see if adding radiation can boost your body's response to treatment.
This trial tests a new drug, ivonescimab, combined with standard chemotherapy before surgery for people with high-risk early-stage triple negative breast cancer. The goal is to see if adding this drug improves treatment response.
This trial tests adding ivermectin (a common anti-parasitic drug) to your current immunotherapy. The hope is that ivermectin may help the immunotherapy work better against your cancer.
This trial tests a new immunotherapy drug (cadonilimab) combined with a chemotherapy (eribulin) against chemotherapy alone for triple-negative breast cancer that has come back or spread. If you receive the combination, the goal is to see if it helps control the cancer better or for longer.
Hear when a new Anatomic Stage IV Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.